Hospitals and health systems are clinging tenaciously to the belief that their economic survival depends on their embracing continuous quality improvement and Lean methods. After all, in a time of ratcheted-down reimbursement, the need for a little belt-tightening and quality improvement seems obvious.
The 100 Rising Stars in this, the inaugural Global Corporate Venturing awards, represent the top 1% of the industry.
Global Corporate Venturing (GCV) selected these stars as representing the brightest prospects, and those who have already been changing the industry. The selection process involved researching more than 10,000 industry professionals across more than 1,000 corporate venturing units to identify these stars. GCV was looking for those below the top rank of the venturing hierarchy in long-established units, based on their deals, career development so far, being an heir apparent and being the glue in the unit.
Wednesday, February 17, 2016 – National Press Club 529 14th St. NW, 13th Floor Washington, D.C.
Kauffman Foundation President and CEO, Wendy Guillies, will present the 2016 State of Entrepreneurship Address highlighting an actionable policy agenda for renewing economic growth. “America’s New Entrepreneurial Growth Agenda” will present recommendations culled from some of the nation’s foremost thinkers on how to foster dynamism, entrepreneurship, and economic opportunity.
Following the address, a panel of contributors will present recommendations from “America’s New Entrepreneurial Growth Agenda,” and policy leaders will share their own insights.
The UM BioPark-based PathSensors, Inc. has been awarded a new firm fixed price contract through the U.S. Department of Homeland Security for the design and development of a CANARY® detection system for biosecurity. The focus of phase I of this research contract will be on the development of biosensors for Abrin and Ebola. The research supported by this contract will further enhance the robustness of the CANARY® technology opening up a broad range of deployment opportunities for quick and accurate detection of harmful pathogens.
Dubbed the Apollo Therapeutics, the new fund will see the three pharma companies work with Imperial College London, University College London and the University of Cambridge. Together they aim to “significantly improving the speed and potential of university research being translated into novel medicines”.
Leidos Holdings Inc. (NYSE: LDOS) CEO Roger Krone describes his company’s new agreement to combine with Lockheed Martin Corp.’s (NYSE: LMT) Information Systems & Global Solutions business as a landmark moment for the government services space. “I am convinced that this transaction is the kind of event that is often sought after but rarely found,” Krone said in a conference call Tuesday after the $5 billion deal was announced.
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior unsecured notes that will mature on February 1, 2023 (the Notes). The Notes will be offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Novavax also expects to grant the initial purchasers of the Notes an option to purchase up to an additional $30 million aggregate principal amount of the Notes, solely to cover over-allotments.
The Food and Drug Administration aims to ensure hackers can’t remotely access or control medical devices, and it’s asking the private sector to do more to protect those devices.
Earlier this month, FDA issued draft guidance directing manufacturers to conduct “postmarket” evaluation of their devices, ensuring device security vulnerabilities won’t affect clinical performance.
Alexandria is the largest and leading urban office REIT uniquely focused on collaborative science and technology campuses in AAA innovation cluster locations. The firm currently has more than 19 million rentable square feet of operating properties, as well as development and redevelopment projects under construction, with another 11.6 million square feet in near-term and future ground-up development projects. Alexandria was the first to pioneer this niche under CEO Joel Marcus’ vision when he founded the company in 1994. Since then, the firm has established a dominant market presence across the industry in locations such as Greater Boston/Cambridge, San Francisco, New York City, San Diego, Seattle, Maryland and Research Triangle Park.
Stephanie Fertig and Kory Hallett from the National Institutes of Health (NIH) will give an overview of SBIR and STTR Small Business programs at the NIH.
The talk will include:
At the end of their presentation, the speakers will respond to questions from the audience.
If you want to find ways to expand your biomedical startup using NIH funding, you won’t want to miss this webinar!
